# Market Mischief: Flat Futures & Oil's Limp Dive!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-03-18T14:01:17.150Z
Source: https://newsyai.com/edition/66cce697-7baa-469c-a250-4cf913cb55f1
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# Futures Flat-Fart, Oil Limp-Dick Drop: Lululemon Guidance Gutterball & Microcap Moon-Masturbate Mayhem!

**Premarket prick-tease**—**Dow futures +0.15% ~47,417**[[1]](https://finance.yahoo.com/quote/S260313C00018000), **S&P +0.13% ~6,782**[[1]](https://finance.yahoo.com/quote/S260313C00018000), **Nasdaq +0.18% ~25,060**[[1]](https://finance.yahoo.com/quote/S260313C00018000) as Iran boner bonks out—**WTI crude $94.75 -1.52%** de-escalation deflate.[[2]](https://tradingeconomics.com/commodity/crude-oil) LULU earnings cum-dump despite beat, SWMR defense dong debut, AIM biotech ball-buster. Bulls humping hope, bears bitching bust—my balls-to-wall breakdown.[[3]](https://www.benzinga.com/premarket)

---

## 1) Lululemon (LULU): “Int'l Growth Gush” vs “Guidance Gut-Punch & Founder Feud Fiasco”

**Why it’s loud**  
**LULU** slipping **-2% pre to ~$220** post-Q4 *beat* (EPS $5.01 > $4.79 est., rev $3.641B > $3.587B), but FY26 guide *sags*: rev below est., NA demand dick-flop, tariffs/taxes titty-twist, founder proxy prick-fight.[[4]](https://corporate.lululemon.com/media/press-releases/2026/03-17-2026-200620717)[[5]](https://www.investing.com/news/earnings/lululemon-stock-slips-after-hours-on-soft-quarterly-and-annual-guidance-4566808)[[6]](https://www.reuters.com/sustainability/sustainable-finance-reporting/lululemon-forecasts-annual-revenue-profit-below-estimates-2026-03-17)

**Bull case (yoga pants yield bonanza)**  
Int'l rev rocket (China/APAC beast-mode offsets NA whiff), full-yr rev +5% to $11.1B, gross margin hold—tariff offset via pricing power, ex-Levi CEO board boost = turnaround thrust.[[4]](https://corporate.lululemon.com/media/press-releases/2026/03-17-2026-200620717)[[7]](https://finance.yahoo.com/news/lululemon-athletica-inc-lulu-q4-030155910.html)

**Bear case (athleisure ass-clown apocalypse)**  
Q1/FY26 guide *misses* est. (profit dip 2nd yr), NA men's slowdown + founder Chip Wilson's "mediocre" management bitch-slap, tariff dong = margin mutilation in $50B+ apparel arena.[[8]](https://daytraders.com/news/2026/03/18/lululemon-stock-under-pressure-from-founder-concerns-weak-outlook)[[9]](https://www.bloomberg.com/news/articles/2026-03-17/lululemon-gives-weak-sales-outlook-adding-to-company-s-troubles)

**My take, first principles (premium panty moat vs consumer cockblock)**  
Boil the leggings: $200B+ athleisure TAM craves LULU's cult cachet, int'l 20%+ comps = escape velocity—but NA 0% guide screams recession rimjob. Proxy porn distracts. **Dip buy $210-215**, **$240/$260 calls** rebound ride—**puts $200** founder flop. Risk: Tariff tsunami.[[4]](https://corporate.lululemon.com/media/press-releases/2026/03-17-2026-200620717)

---

## 2) Swarmer (SWMR): “AI Defense Dong-Slam IPO” vs “Ukrainian Unicorn Unicorn-Fart”

**Why it’s loud**  
**SWMR** ripping **+27% (up to +60% intraday tease) pre to ~$39.48** on *Nasdaq debut*—Ukrainian AI drone/drone-killer startup amid Iran oil jizz-jam, investor geo-gamble galore.[[3]](https://www.benzinga.com/premarket)[[10]](https://www.benzinga.com/trading-ideas/movers/26/03/51320030/market-moving-news-for-march-18th)

**Bull case (proxy war profit prick)**  
$100B+ defense AI TAM exploding (Ukraine lab-rat edge), Iran/Hormuz hype = contract cumshot, IPO pop signals VC vomit-to-value—peer multiples scream $100+ PT.[[3]](https://www.benzinga.com/premarket)

**Bear case (warlord wannabe wipeout)**  
Fresh IPO lockup leak risk, unprofitable Ukraine ops = capex corpse, hype > hock in crowded drone dogfight (Anduril/AeroVironment ass-pounders).[[3]](https://www.benzinga.com/premarket)

**My take, first principles (autonomous kill-chain king vs vaporware volatility)**  
Core the code: AI autonomy crushes manned meat-grinder costs, SWMR's swarm tech = F-35 fuck-you scale—but war whims whack. Oil deflate dilutes. **IPO dip $35-37**, **$50/$60 calls** conflict cream—**puts $30** peace pipe. Risk: De-escalation dump.[[3]](https://www.benzinga.com/premarket)

---

## 3) AIM ImmunoTech (AIM): “Biotech Booster Blast-Off” vs “Dilution Diarrhea Debacle”

**Why it’s loud**  
**AIM** exploding **+98.6% pre to $1.41**—immuno-onco hype resurgence post-Phase 2 encouragers, rights offering residue rocket fuel in premarket pump-party.[[3]](https://www.benzinga.com/premarket)[[11]](https://www.rttnews.com/3618175/aim-immunotech-announces-encouraging-results-from-phase-2-duripanc-study-stock-up-in-pre-market.aspx)

**Bull case (Ampligen ass-kicker ace)**  
Phase 2 pancreatic data dong (DURIPANC tease), $1.8M rights raise runway for trials—long COVID/cancer combo = multibagger moat in $200B immuno TAM.[[12]](https://aimimmuno.com/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million)[[11]](https://www.rttnews.com/3618175/aim-immunotech-announces-encouraging-results-from-phase-2-duripanc-study-stock-up-in-pre-market.aspx)

**Bear case (serial spunk-squanderer)**  
Chronic diluters (recent Series G prefs, past $8M offer tanked 50%), bleeder losses, trial tardiness = biotech black hole bait.[[13]](https://www.msn.com/en-us/money/companies/aim-immunotech-slumps-50-after-pricing-8m-securities-offering/ar-AA1JvRuY?apiversion=v2&batchservertelemetry=1&domshim=1&noservercache=1&noservertelemetry=1&ocid=finance-verthp-feeds&renderwebcomponents=1&wcseo=1)

**My take, first principles (interferon immunity edge vs cash-burn clownery)**  
Peel the peptide: Ampligen's unique TLR3 agonist = orphan drug orphan slayer, but exec dysfunction = dilution deluge destiny. Momentum meat: **Dip $1.20-1.30**, **$2/$2.50 calls** trial thrust—**puts $1.00** fade fart. Risk: Data dud.[[11]](https://www.rttnews.com/3618175/aim-immunotech-announces-encouraging-results-from-phase-2-duripanc-study-stock-up-in-pre-market.aspx)

---

## Tape-Side Tactics (load the mag or swallow the shame)

- **LULU**: **$210-215** guidance grab; **$240C/$260C** spreads, **P$200** outlook oof.[[4]](https://corporate.lululemon.com/media/press-releases/2026/03-17-2026-200620717)  
- **SWMR**: **$35-37** IPO ass-plug; **$50C/$60C**, **P$30** war wank-off.[[3]](https://www.benzinga.com/premarket)  
- **AIM**: **$1.20-1.30** biotech ball-sack; **$2C/$2.50C**, **P$1.00** rights rimjob.[[11]](https://www.rttnews.com/3618175/aim-immunotech-announces-encouraging-results-from-phase-2-duripanc-study-stock-up-in-pre-market.aspx)  

Iran limp or reload? Guidance gloom or yoga yen? DYOR, hump or hump-dump.
